Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a single arm phase 1b/2 evaluation of the combination of oregovomab, and bevacizumab,
paclitaxel carboplatin in adult subjects with CA125-associated, advanced recurrent epithelial
ovarian, fallopian tube or peritoneal carcinoma (FIGO Stage III/IV) with BRCA-wild type,
previously treated with 1 prior lines of therapy, and with platinum free intervals of >6
months since last platinum-based treatment.